Semaglutide
GLP-1 analog focused on appetite regulation and metabolic control.
ClinicalRegulated medicationInjectableMetabolic
Key facts
Common routesSubcutaneous
Half-life~1 week
Typical range0.25-1 mg/week
Resumen
Semaglutide is a long-acting GLP-1 receptor agonist with well-established use in metabolic medicine. This page focuses on general research context, not prescription guidance.
Effects are driven by appetite regulation, delayed gastric emptying, and improved glycemic control in clinical settings.
Notas sobre el mecanismo
GLP-1 receptor activation
Enhances insulin secretion, suppresses glucagon, and slows gastric emptying.
Appetite modulation
Central appetite pathways reduce caloric intake and improve adherence.
Patrones de dosificación
Titration strategy
Clinical protocols emphasize gradual titration to reduce GI side effects.
Maintenance
Weekly dosing with dose adjustments based on tolerance and response.
Resumen de evidencia
Evidence base is robust with randomized trials in metabolic and obesity populations. Outcomes include weight reduction and cardiometabolic markers.
Clinical trials
Large-scale trials show statistically significant weight loss outcomes.
Real-world outcomes
Weight regain after discontinuation is common without lifestyle support.
Consideraciones de seguridad
GI symptoms, nausea, and appetite suppression are the most common effects. Use is contraindicated in certain endocrine conditions.
Common cautions
- Molestias GI y vaciado gástrico retardado
- Advertencias de pancreatitis en poblaciones susceptibles
- Advertencias de tumores de células C tiroideas en modelos animales